Ítem
Acceso Abierto
Proximity of first sexual intercourse to menarche and risk of high-grade cervical disease
Título de la revista
Autores
Ruíz Sternberg, Ángela María
Ruiz, Jaime Enrique
Gavilanes, Andrés Velásquez
Eriksson, Tiina
Lehtinen, Matti
Pérez, Gonzalo
Sings, Heather L.
James, Margaret K.
Haupt, Richard M.
Archivos
Fecha
2012
Directores
ISSN de la revista
Título del volumen
Editor
Buscar en:
Métricas alternativas
Resumen
Abstract
Background We assessed if risk of developing cervical intraepithelial neoplasia grade 2/3 (CIN2/3) or adenocarcinoma in situ (AIS) is associated with a short interval between menarche and first sexual intercourse (FSI).Methods A total of 1009 Colombian and 1012 Finnish females, aged 16-23, who were enrolled in the phase 3 trials of a quadrivalent human papillomavirus (HPV) 6/11/16/18 vaccine had nonmissing data for age of menarche and FSI. The impact of menarche interval on the odds of developing CIN2-3/AIS was evaluated in placebo recipients who were DNA negative to HPV 6/11/16/18/31/33/35/39/45/51/52/56/58/59 and seronegative to HPV 6/11/16/18 at day 1, and had a normal Pap result at day 1 and month 7, thus approximating sexually naive adolescents (n = 504).Results The mean age of menarche and FSI was 12.4 and 16.0 years, respectively. Among the women approximating sexually naive adolescents, 18 developed CIN2-3/AIS. Compared with women who postponed FSI beyond 3 years of menarche, those with FSI within 3 years of menarche had a greater risk of cytologic abnormalities (odds ratio [OR], 1.65; 95% confidence interval [CI], 1.02-2.68; P =. 04) and CIN2-3/AIS (OR, 3.56; 95% CI, 1.02-12.47; P =. 05).Conclusions A short interval between menarche and FSI was a risk factor for cytologic abnormalities and high-grade cervical disease. These data emphasize the importance of primary prevention through education and vaccination.Clinical Trials Registration. NCT00092521 and NCT00092534. © 2012 The Author.
Palabras clave
Keywords
Oral contraceptive agent , phase iii as topic , Virus dna , Wart virus vaccine , Adolescent , Adult , Article , Cancer risk , Colombian , Colposcopy , Condom , Confidence interval , Ethnic group , Female , Finnish , Human , Human papillomavirus type 11 , Human papillomavirus type 16 , Human papillomavirus type 18 , Human papillomavirus type 31 , Human papillomavirus type 33 , Human papillomavirus type 35 , Human papillomavirus type 39 , Human papillomavirus type 45 , Human papillomavirus type 51 , Human papillomavirus type 52 , Human papillomavirus type 56 , Human papillomavirus type 58 , Human papillomavirus type 59 , Human papillomavirus type 6 , Major clinical study , Menarche , Papanicolaou test , Phase 3 clinical trial (topic) , Polymerase chain reaction , Post hoc analysis , Priority journal , Randomized controlled trial (topic) , Risk assessment , Sexual behavior , Sexual intercourse , Uterine cervix biopsy , Uterine cervix carcinoma in situ , Uterine cervix cytology , Wart virus , Adenocarcinoma , Adolescent , Adult , Cervical intraepithelial neoplasia , Clinical trials , Coitus , Colombia , Female , Finland , Humans , Menarche , Papillomavirus infections , Risk assessment , Sexual behavior , Time factors , Uterine cervical neoplasms , Young adult
